Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard L. Kaufman, M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. UM1CA186716 (MEHNERT, JANICE) Mar 19, 2014 - Feb 29, 2020
    Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics
    Role: Co-Principal Investigator
  2. R01CA093696 (KAUFMAN, HOWARD L.) Sep 16, 2002 - Aug 31, 2005
    Role: Principal Investigator
  3. K08CA079881 (KAUFMAN, HOWARD L.) Aug 1, 2000 - Jul 31, 2004
    Role: Principal Investigator
  4. R03CA080647 (KAUFMAN, HOWARD L.) Sep 30, 1998 - Sep 29, 2001
    Role: Principal Investigator
  5. R41HD034012 (KAUFMAN, HOWARD L.) Aug 18, 1995 - Aug 15, 1996
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. PMID: 31272507.
  2. Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G, ?hrling K, Kaufman HL. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer. 2019 Jun 06; 7(1):145. PMID: 31171039.
  3. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 May 22; 7(1):131. PMID: 31113486.
  4. Kaufman HL, Atkins MB, Subedi P, Wu J, Chambers J, Joseph Mattingly T, Campbell JD, Allen J, Ferris AE, Schilsky RL, Danielson D, Lichtenfeld JL, House L, Selig WKD. The promise of Immuno-oncology: implications for defining the value of cancer treatment. J Immunother Cancer. 2019 May 17; 7(1):129. PMID: 31101066.
  5. Bommareddy PK, Zloza A, Rabkin SD, Kaufman HL. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. Oncoimmunology. 2019; 8(7):1591875. PMID: 31143509.
  6. Hennessy ML, Bommareddy PK, Boland G, Kaufman HL. Oncolytic Immunotherapy. Surg Oncol Clin N Am. 2019 Jul; 28(3):419-430. PMID: 31079797.
  7. Bommareddy PK, Lowe DB, Kaufman HL, Rabkin SD, Saha D. Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. J Biol Methods. 2019; 6(2). PMID: 31123687.
  8. Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry. J Immunother Cancer. 2019 Mar 27; 7(1):84. PMID: 30917871.
  9. Bommareddy PK, Rabkin SD, Kaufman HL. Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. Oncoimmunology. 2019; 8(4):e1571390. PMID: 30906668.
  10. Ugolini H, Bryan J, Hennessy M, Kaufman HL, D'Angelo S. Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. Clin J Oncol Nurs. 2019 Feb 01; 23(1):E1-E9. PMID: 30682006.
    Citations:    Fields:    
  11. Kaufman HL, Bommareddy PK. Two roads for oncolytic immunotherapy development. J Immunother Cancer. 2019 Feb 01; 7(1):26. PMID: 30709365.
    Citations:    Fields:    
  12. Bommareddy PK, Aspromonte S, Zloza A, Rabkin SD, Kaufman HL. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Sci Transl Med. 2018 Dec 12; 10(471). PMID: 30541787.
  13. D'Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, Kiecker F, Rabinowits G, Terheyden P, Zwiener I, Bajars M, Hennessy M, Kaufman HL. Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. JAMA Oncol. 2018 Sep 01; 4(9):e180077. PMID: 29566106.
    Citations: 4     Fields:    
  14. Kaufman HL, Schwartz LH, William WN, Sznol M, Fahrbach K, Xu Y, Masson E, Vergara-Silva A. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2018 Nov; 144(11):2245-2261. PMID: 30132118.
    Citations:    Fields:    Translation:Humans
  15. Kaufman HL, Dias Barbosa C, Guillemin I, Lambert J, Mahnke L, Bharmal M. Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. Patient. 2018 08; 11(4):439-449. PMID: 29512061.
    Citations:    Fields:    
  16. Bommareddy PK, Shettigar M, Kaufman HL. Author Correction: Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 Aug; 18(8):536. PMID: 29930315.
    Citations:    Fields:    
  17. Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol. 2018 Aug; 18(8):498-513. PMID: 29743717.
    Citations: 3     Fields:    
  18. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 Jul 11; 6(1):69. PMID: 29996914.
    Citations:    Fields:    
  19. Marciscano AE, Gulley JL, Kaufman HL. Avelumab: is it time to get excited? Expert Rev Anticancer Ther. 2018 09; 18(9):815-821. PMID: 29939083.
    Citations:    Fields:    
  20. Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa J. Immune oncology, immune responsiveness and the theory of everything. J Immunother Cancer. 2018 06 05; 6(1):50. PMID: 29871670.
    Citations:    Fields:    
  21. Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018. JAMA Oncol. 2018 Jun 01; 4(6):857-858. PMID: 29621376.
    Citations: 1     Fields:    
  22. Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44. PMID: 29848375.
    Citations: 1     Fields:    
  23. Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest. 2018 Jun 01; 128(6):2325-2338. PMID: 29533922.
    Citations:    Fields:    
  24. Chan IS, Bhatia S, Kaufman HL, Lipson EJ. Immunotherapy for Merkel cell carcinoma: a turning point in patient care. J Immunother Cancer. 2018 03 23; 6(1):23. PMID: 29566749.
    Citations: 2     Fields:    
  25. Bommareddy PK, Kaufman HL. Unleashing the therapeutic potential of oncolytic viruses. J Clin Invest. 2018 Apr 02; 128(4):1258-1260. PMID: 29504947.
    Citations:    Fields:    
  26. Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare S, Saunders T, Kane M, Sokol L, Stein MN, Poplin E, Rodriguez-Rodriguez L, Silk AW, Aisner J, Chan N, Malhotra J, Frankel M, Kaufman HL, Ali S, Ross JS, White EP, Bhanot G, Ganesan S. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst. 2018 03 01; 110(3):316-320. PMID: 29155997.
    Citations: 9     Fields:    
  27. Gartrell RD, Marks DK, Hart TD, Li G, Davari DR, Wu A, Blake Z, Lu Y, Askin KN, Monod A, Esancy CL, Stack EC, Jia DT, Armenta PM, Fu Y, Izaki D, Taback B, Rabadan R, Kaufman HL, Drake CG, Horst BA, Saenger YM. Quantitative Analysis of Immune Infiltrates in Primary Melanoma. Cancer Immunol Res. 2018 04; 6(4):481-493. PMID: 29467127.
    Citations:    Fields:    
  28. Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after =1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018 Jan 19; 6(1):7. PMID: 29347993.
    Citations: 8     Fields:    
  29. Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N, Morse MA, Wong MKK, Dutcher JP. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017 12 19; 5(1):102. PMID: 29254506.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  30. Kaufman HL, Hunger M, Hennessy M, Schlichting M, Bharmal M. Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncol. 2018 Feb; 14(3):255-266. PMID: 29219612.
    Citations: 1     Fields:    Translation:Humans
  31. Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, Mehnert JM, Sullivan R, Lovly CM, Sosman J, Johnson DB, Bhanot G, Ganesan S. Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precis Oncol. 2017; 2017. PMID: 29951597.
    Citations: 1     
  32. Hughes T, Broucek J, Iodice G, Bommareddy PK, Basu S, Kaufman HL. Metastasectomy following incomplete response to high-dose interleukin-2. J Surg Oncol. 2018 Mar; 117(4):572-578. PMID: 29165819.
    Citations:    Fields:    Translation:Humans
  33. Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 11 21; 5(1):95. PMID: 29162153.
    Citations: 28     Fields:    Translation:Humans
  34. Cohen-Solal KA, Kaufman HL, Lasfar A. Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development. Pigment Cell Melanoma Res. 2018 03; 31(2):241-252. PMID: 29090514.
    Citations:    Fields:    Translation:HumansCells
  35. Everett AS, Pavlidakey PG, Contreras CM, De Los Santos JF, Kim JY, McKee SB, Kaufman HL, Conry RM. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. J Cutan Pathol. 2018 Jan; 45(1):48-53. PMID: 28940544.
    Citations: 1     Fields:    Translation:Humans
  36. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 Jun 10; 36(17):1658-1667. PMID: 28981385.
    Citations: 23     Fields:    
  37. Bommareddy PK, Kaufman HL. Avelumab and other recent advances in Merkel cell carcinoma. Future Oncol. 2017 Dec; 13(30):2771-2783. PMID: 28976209.
    Citations: 1     Fields:    Translation:HumansCells
  38. Kaufman HL. Finding gold in tumour immunotherapy. Lancet Oncol. 2017 10; 18(10):e561. PMID: 28971820.
    Citations:    Fields:    Translation:Humans
  39. Marabondo S, Kaufman HL. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opin Drug Saf. 2017 Dec; 16(12):1347-1357. PMID: 28929820.
    Citations: 3     Fields:    Translation:Humans
  40. Kaufman HL, Andtbacka RHI, Collichio FA, Wolf M, Zhao Z, Shilkrut M, Puzanov I, Ross M. Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. J Immunother Cancer. 2017 09 19; 5(1):72. PMID: 28923101.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  41. Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. Oncoimmunology. 2017; 6(10):e1338237. PMID: 29123950.
    Citations: 5     
  42. Kaufman HL. Rational Combination Immunotherapy: Understand the Biology. Cancer Immunol Res. 2017 05; 5(5):355-356. PMID: 28465453.
    Citations: 2     Fields:    Translation:HumansAnimals
  43. Patel A, Kaufman HL, Disis ML. Next generation approaches for tumor vaccination. Chin Clin Oncol. 2017 Apr; 6(2):19. PMID: 28482672.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  44. Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017 Jun; 13(14):1263-1279. PMID: 28350180.
    Citations: 9     Fields:    Translation:Humans
  45. Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 Aug 01; 23(15):4163-4169. PMID: 28331050.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  46. Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunother Cancer. 2017; 5:16. PMID: 28239469.
    Citations: 37     Fields:    Translation:HumansAnimals
  47. Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017 Feb; 18(1):1-15. PMID: 27988837.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  48. Bommareddy PK, Silk AW, Kaufman HL. Intratumoral Approaches for the Treatment of Melanoma. Cancer J. 2017 Jan/Feb; 23(1):40-47. PMID: 28114253.
    Citations: 2     Fields:    Translation:HumansAnimals
  49. Harrington KJ, Andtbacka RH, Collichio F, Downey G, Chen L, Szabo Z, Kaufman HL. Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. Onco Targets Ther. 2016; 9:7081-7093. PMID: 27895500.
    Citations: 6     
  50. Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 08; 7(45):74380-74392. PMID: 27602582.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  51. Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clin Genitourin Cancer. 2017 02; 15(1):31-41.e4. PMID: 27916626.
    Citations:    Fields:    Translation:Humans
  52. Zloza A, Dharmadhikari ND, Huelsmann EJ, Broucek JR, Hughes T, Kohlhapp FJ, Kaufman HL. Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunol Immunother. 2017 01; 66(1):9-16. PMID: 27757560.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  53. Kohlhapp FJ, Huelsmann EJ, Lacek AT, Schenkel JM, Lusciks J, Broucek JR, Goldufsky JW, Hughes T, Zayas JP, Dolubizno H, Sowell RT, Kühner R, Burd S, Kubasiak JC, Nabatiyan A, Marshall S, Bommareddy PK, Li S, Newman JH, Monken CE, Shafikhani SH, Marzo AL, Guevara-Patino JA, Lasfar A, Thomas PG, Lattime EC, Kaufman HL, Zloza A. Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Rep. 2016 10 18; 17(4):957-965. PMID: 27760326.
    Citations: 6     Fields:    Translation:AnimalsCells
  54. Alva A, Daniels GA, Wong MK, Kaufman HL, Morse MA, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544. PMID: 27714434.
    Citations: 9     Fields:    Translation:Humans
  55. Buchbinder EI, Gunturi A, Perritt J, Dutcher J, Aung S, Kaufman HL, Ernstoff MS, Miletello GP, Curti BD, Daniels GA, Patel SP, Kirkwood JM, Hallmeyer S, Clark JI, Gonzalez R, Richart JM, Lutzky J, Morse MA, Sullivan RJ, McDermott DF. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016; 4:52. PMID: 27660706.
    Citations: 5     Fields:    
  56. Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer. 2016; 4:53. PMID: 27660707.
    Citations: 21     Fields:    
  57. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct; 17(10):1374-1385. PMID: 27592805.
    Citations: 113     Fields:    Translation:HumansCTClinical Trials
  58. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2016 08 30; 15(9):660. PMID: 30907381.
  59. Hirshfield KM, Tolkunov D, Zhong H, Ali SM, Stein MN, Murphy S, Vig H, Vazquez A, Glod J, Moss RA, Belyi V, Chan CS, Chen S, Goodell L, Foran D, Yelensky R, Palma NA, Sun JX, Miller VA, Stephens PJ, Ross JS, Kaufman H, Poplin E, Mehnert J, Tan AR, Bertino JR, Aisner J, DiPaola RS, Rodriguez-Rodriguez L, Ganesan S. Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. Oncologist. 2016 Nov; 21(11):1315-1325. PMID: 27566247.
    Citations: 8     Fields:    
  60. Jhawar SR, Kaufman HL, Goyal S. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016 Nov 15; 122(22):3576-3577. PMID: 27495907.
    Citations: 1     Fields:    
  61. Emens LA, Butterfield LH, Hodi FS, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016; 4:42. PMID: 27437105.
    Citations: 6     Fields:    
  62. Andtbacka RH, Agarwala SS, Ollila DW, Hallmeyer S, Milhem M, Amatruda T, Nemunaitis JJ, Harrington KJ, Chen L, Shilkrut M, Ross M, Kaufman HL. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head Neck. 2016 12; 38(12):1752-1758. PMID: 27407058.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  63. Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM. IFN-? cancer immunotherapy: new kid on the block. Immunotherapy. 2016 07; 8(8):877-88. PMID: 27381684.
    Citations: 3     Fields:    Translation:HumansAnimals
  64. Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL. Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Ann Surg Oncol. 2016 12; 23(13):4169-4177. PMID: 27342831.
    Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
  65. Kaufman HL, Butterfield LH, Coulie PG, Demaria S, Ferris RL, Galon J, Khleif SN, Mellman I, Ohashi PS, Overwijk WW, Topalian SL, Marincola FM. Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. J Immunother Cancer. 2016; 4:37. PMID: 27330810.
    Citations:    Fields:    
  66. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. J Clin Oncol. 2016 08 01; 34(22):2619-26. PMID: 27298410.
    Citations: 66     Fields:    Translation:HumansCellsCTClinical Trials
  67. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, Ali S, Ross JS, Pavlick DC, Bhanot G, White EP, DiPaola RS, Lovell A, Cheng J, Ganesan S. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016 06 01; 126(6):2334-40. PMID: 27159395.
    Citations: 40     Fields:    Translation:Humans
  68. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016; 4:12. PMID: 26981242.
    Citations: 11     Fields:    
  69. Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI, Ye F, Guminski A, Puzanov I, Lawrence DP, Buchbinder EI, Mudigonda T, Spencer K, Bender C, Lee J, Kaufman HL, Menzies AM, Hassel JC, Mehnert JM, Sosman JA, Long GV, Clark JI. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol. 2016 Feb; 2(2):234-40. PMID: 26633184.
    Citations: 56     Fields:    Translation:Humans
  70. Koshenkov VP, Broucek J, Kaufman HL. Surgical Management of Melanoma. Cancer Treat Res. 2016; 167:149-79. PMID: 26601862.
    Citations: 1     Fields:    Translation:Humans
  71. Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM. Biomarkers for Immunotherapy: Current Developments and Challenges. Am Soc Clin Oncol Educ Book. 2016; 35:e493-503. PMID: 27249758.
    Citations: 9     Fields:    Translation:HumansCells
  72. Kohlhapp FJ, Kaufman HL. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clin Cancer Res. 2016 Mar 01; 22(5):1048-54. PMID: 26719429.
    Citations: 25     Fields:    Translation:HumansCells
  73. Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma. Cancer Biol Ther. 2015 Sep 29; 0. PMID: 26418961.
    Citations: 4     Fields:    
  74. Stein MN, Hussain M, Stadler WM, Liu G, Tereshchenko IV, Goodin S, Jeyamohan C, Kaufman HL, Mehnert J, DiPaola RS. A Phase II Study of AT-101 to Overcome Bcl-2--Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prostate Cancer. Clin Genitourin Cancer. 2016 Feb; 14(1):22-7. PMID: 26476589.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  75. Kohlhapp FJ, Zloza A, Kaufman HL. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc). 2015 Sep; 51(9):549-58. PMID: 26488034.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  76. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015 Sep; 14(9):642-62. PMID: 26323545.
    Citations: 115     Fields:    Translation:HumansAnimalsCells
  77. Goyal S, Silk AW, Tian S, Mehnert J, Danish S, Ranjan S, Kaufman HL. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA Oncol. 2015 Aug; 1(5):668-76. PMID: 26181286.
    Citations: 13     Fields:    Translation:Humans
  78. Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biol. 2015 Jun 25; 16:133. PMID: 26109056.
    Citations: 40     Fields:    Translation:HumansCells
  79. Kaufman HL. Combination Immunotherapy for Melanoma. JAMA Oncol. 2015 Jun; 1(3):387-8. PMID: 26181189.
    Citations: 1     Fields:    Translation:Humans
  80. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol. 2015 Sep 01; 33(25):2780-8. PMID: 26014293.
    Citations: 307     Fields:    Translation:HumansCellsCTClinical Trials
  81. Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, Schenkel JM, Masopust D, Zloza A, Kaufman HL. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. J Immunother Cancer. 2015; 3:18. PMID: 25992289.
    Citations: 10     Fields:    
  82. Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol. 2015 Mar; 16(3):326. PMID: 25777572.
    Citations: 9     Fields:    Translation:HumansCells
  83. de Vries CR, Kaufman HL, Lattime EC. Oncolytic viruses: focusing on the tumor microenvironment. Cancer Gene Ther. 2015 Mar; 22(4):169-71. PMID: 25721204.
    Citations: 4     Fields:    Translation:HumansCells
  84. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC. Consensus nomenclature for CD8+ T cell phenotypes in cancer. Oncoimmunology. 2015 Apr; 4(4):e998538. PMID: 26137416.
    Citations: 26     
  85. Goldufsky J, Wood S, Hajihossainlou B, Rehman T, Majdobeh O, Kaufman HL, Ruby CE, Shafikhani SH. Pseudomonas aeruginosa exotoxin T induces potent cytotoxicity against a variety of murine and human cancer cell lines. J Med Microbiol. 2015 Feb; 64(Pt 2):164-73. PMID: 25627204.
    Citations: 6     Fields:    Translation:HumansAnimalsCells
  86. Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2015 Apr; 64(4):459-65. PMID: 25603775.
    Citations: 6     Fields:    Translation:Humans
  87. Kaufman HL. Precision immunology: the promise of immunotherapy for the treatment of cancer. J Clin Oncol. 2015 Apr 20; 33(12):1315-7. PMID: 25605852.
    Citations:    Fields:    Translation:HumansCells
  88. Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015; 15(12):1389-403. PMID: 26558498.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  89. Doscas ME, Williamson AJ, Usha L, Bogachkov Y, Rao GS, Xiao F, Wang Y, Ruby C, Kaufman H, Zhou J, Williams JW, Li Y, Xu X. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress. Neoplasia. 2014 Oct; 16(10):824-34. PMID: 25379019.
    Citations: 8     Fields:    Translation:HumansCells
  90. Zloza A, Kim DW, Broucek J, Schenkel JM, Kaufman HL. High-dose IL-2 induces rapid albumin uptake by endothelial cells through Src-dependent caveolae-mediated endocytosis. J Interferon Cytokine Res. 2014 Nov; 34(11):915-9. PMID: 24963699.
    Citations: 3     Fields:    Translation:HumansCells
  91. Wong MK, Kaufman HL, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. J Immunother Cancer. 2014; 2:20. PMID: 25031835.
    Citations: 2     Fields:    
  92. Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer. 2014; 2:11. PMID: 24971166.
    Citations: 42     Fields:    
  93. Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. J Transl Med. 2014 May 06; 12:113. PMID: 24885155.
    Citations: 1     Fields:    Translation:HumansCells
  94. Lu R, Wu S, Zhang Y, Xia Y, Huelsmann EJ, Lacek AT, Nabatiyan A, Richards MH, Narasipura SD, Lutgen V, Chen H, Kaufman HL, Chen D, Al-Harthi L, Zloza A, Sun J. HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice. AIDS Res Hum Retroviruses. 2014 Jul; 30(7):677-84. PMID: 24593860.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  95. Kaufman HL, Kim DW, Kim-Schulze S, DeRaffele G, Jagoda MC, Broucek JR, Zloza A. Results of a randomized phase I gene therapy clinical trial of nononcolytic fowlpox viruses encoding T cell costimulatory molecules. Hum Gene Ther. 2014 May; 25(5):452-60. PMID: 24484178.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  96. Kaufman HL, Wong MK, Daniels GA, McDermott DF, Aung S, Lowder JN, Morse MA. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J Pers Med. 2014 Mar 07; 4(1):52-64. PMID: 25562142.
    Citations: 7     
  97. Kaufman HL. Melanoma as a model for precision medicine in oncology. Lancet Oncol. 2014 Mar; 15(3):251-3. PMID: 24508105.
    Citations: 3     Fields:    Translation:Humans
  98. Zloza A, Kim DW, Kim-Schulze S, Jagoda MC, Monsurro V, Marincola FM, Kaufman HL. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer. 2014; 2:1. PMID: 24829758.
    Citations: 7     Fields:    
  99. Hughes T, Coffin RS, Lilley CE, Ponce R, Kaufman HL. Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virother. 2014; 3:11-20. PMID: 27512660.
    Citations: 1     
  100. Goldufsky J, Sivendran S, Harcharik S, Pan M, Bernardo S, Stern RH, Friedlander P, Ruby CE, Saenger Y, Kaufman HL. Oncolytic virus therapy for cancer. Oncolytic Virother. 2013; 2:31-46. PMID: 27512656.
    Citations: 3     
  101. Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98. PMID: 23982524.
    Citations: 49     Fields:    Translation:Humans
  102. Abern MR, Tsivian M, Coogan CL, Kaufman HL, Polascik TJ. Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control. 2013 Nov; 24(11):1925-33. PMID: 23897487.
    Citations:    Fields:    Translation:Humans
  103. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. PMID: 23731854.
    Citations: 8     Fields:    Translation:HumansAnimals
  104. Batus M, Waheed S, Ruby C, Petersen L, Bines SD, Kaufman HL. Optimal management of metastatic melanoma: current strategies and future directions. Am J Clin Dermatol. 2013 Jun; 14(3):179-94. PMID: 23677693.
    Citations: 11     Fields:    Translation:HumansAnimals
  105. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, Kumar P, Denman CJ, Lacek AT, Kohlhapp FJ, Alamiri A, Hughes T, Bines SD, Kaufman HL, Overbeck A, Mehrotra S, Hernandez C, Nishimura MI, Guevara-Patino JA, Le Poole IC. Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med. 2013 Feb 27; 5(174):174ra28. PMID: 23447019.
    Citations: 19     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  106. Zhang F, Kaufman HL, Deng Y, Drabier R. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. BMC Med Genomics. 2013; 6 Suppl 1:S4. PMID: 23369435.
    Citations: 4     Fields:    Translation:Humans
  107. Clark JM, Kelley B, Titze J, Fung H, Maciejewski J, Nathan S, Rich E, Basu S, Kaufman HL. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology. 2013; 84(2):123-6. PMID: 23235386.
    Citations: 2     Fields:    Translation:Humans
  108. Berinstein NL, Karkada M, Morse MA, Nemunaitis JJ, Chatta G, Kaufman H, Odunsi K, Nigam R, Sammatur L, MacDonald LD, Weir GM, Stanford MM, Mansour M. First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients. J Transl Med. 2012 Aug 03; 10:156. PMID: 22862954.
    Citations: 20     Fields:    Translation:HumansCells
  109. Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Semin Oncol. 2012 Jun; 39(3):263-75. PMID: 22595049.
    Citations: 10     Fields:    Translation:HumansAnimals
  110. Zhang RT, Bines SD, Ruby C, Kaufman HL. TroVax(®) vaccine therapy for renal cell carcinoma. Immunotherapy. 2012 Jan; 4(1):27-42. PMID: 22149999.
    Citations: 3     Fields:    Translation:HumansAnimals
  111. Chen Z, Liu J, Ng HK, Nadarajah S, Kaufman HL, Yang JY, Deng Y. Statistical methods on detecting differentially expressed genes for RNA-seq data. BMC Syst Biol. 2011; 5 Suppl 3:S1. PMID: 22784615.
    Citations: 10     Fields:    
  112. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011 Dec 14; 9:214. PMID: 22168571.
    Citations: 56     Fields:    Translation:Humans
  113. Lazarus M, Kaufman H. An association between corticosteroid use and melanoma recurrence: a case report and review of the literature. Med Oncol. 2012 Sep; 29(3):2018-20. PMID: 21922297.
    Citations:    Fields:    Translation:Humans
  114. Kabaker K, Shell K, Kaufman HL. Vaccines for colorectal cancer and renal cell carcinoma. Cancer J. 2011 Sep-Oct; 17(5):283-93. PMID: 21952277.
    Citations: 2     Fields:    Translation:HumansAnimals
  115. Turner J, Myers JA, Titze J, Kaufman HL, Bines SD. Single-incision laparoscopic surgery for intra-abdominal metastatic melanoma. Am Surg. 2011 Aug; 77(8):E164-5. PMID: 21944502.
    Citations:    Fields:    Translation:Humans
  116. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011 Jun 02; 364(22):2119-27. PMID: 21631324.
    Citations: 240     Fields:    Translation:HumansCTClinical Trials
  117. Abern M, Kaufman HL, Latchamsetty K. An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther. 2011; 4:33-41. PMID: 21691576.
    Citations: 2     
  118. Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer. 2011 May 23; 11:194. PMID: 21605422.
    Citations: 23     Fields:    Translation:HumansCells
  119. Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, Kaufman HL, de Belin J, Kelleher M, Goonewardena M, Naylor S. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother. 2011 Jun; 60(6):829-37. PMID: 21387109.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  120. Kim DW, Krishnamurthy V, Bines SD, Kaufman HL. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development. Hum Vaccin. 2010 Oct; 6(10):784-91. PMID: 20975327.
    Citations: 12     Fields:    Translation:HumansAnimals
  121. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J, Goonewardena M, Naylor S, Harrop R. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15; 16(22):5539-47. PMID: 20881001.
    Citations: 46     Fields:    Translation:HumansCTClinical Trials
  122. Sivendran S, Pan M, Kaufman HL, Saenger Y. Herpes simplex virus oncolytic vaccine therapy in melanoma. Expert Opin Biol Ther. 2010 Jul; 10(7):1145-53. PMID: 20515292.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  123. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol. 2010 Jun; 6(6):941-9. PMID: 20528232.
    Citations: 63     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  124. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010 Mar; 17(3):718-30. PMID: 19915919.
    Citations: 134     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
  125. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71. PMID: 19884534.
    Citations: 176     Fields:    Translation:HumansCellsCTClinical Trials
  126. Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand. Cancer Res. 2009 Nov 01; 69(21):8516-25. PMID: 19843856.
    Citations: 14     Fields:    Translation:AnimalsCells
  127. Wang Q, Ornstein M, Kaufman HL. Imaging the immune response to monitor tumor immunotherapy. Expert Rev Vaccines. 2009 Oct; 8(10):1427-37. PMID: 19803763.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  128. Sabatino M, Kim-Schulze S, Panelli MC, Stroncek D, Wang E, Taback B, Kim DW, Deraffele G, Pos Z, Marincola FM, Kaufman HL. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009 Jun 01; 27(16):2645-52. PMID: 19364969.
    Citations: 60     Fields:    Translation:HumansCellsCTClinical Trials
  129. Mori F, Giannetti P, Peruzzi D, Lazzaro D, Giampaoli S, Kaufman HL, Ciliberto G, La Monica N, Aurisicchio L. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum Gene Ther. 2009 Feb; 20(2):125-36. PMID: 18937552.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  130. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, DeRaffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009 Jan 07; 7:2. PMID: 19128501.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  131. Kim-Schulze S, Kaufman HL. Gene therapy for antitumor vaccination. Methods Mol Biol. 2009; 542:515-27. PMID: 19565920.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  132. Kim-Schulze S, Kim HS, Wainstein A, Kim DW, Yang WC, Moroziewicz D, Mong PY, Bereta M, Taback B, Wang Q, Kaufman HL. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembronic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J Immunol. 2008 Dec 01; 181(11):8112-9. PMID: 19018004.
    Citations: 7     Fields:    Translation:HumansAnimalsCellsPHPublic Health
  133. Kim-Schulze S, Kim HS, Fan Q, Kim DW, Kaufman HL. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009 Feb; 17(2):380-8. PMID: 19034262.
    Citations: 17     Fields:    Translation:AnimalsCells
  134. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ, Conry RM, Urba WJ, Benson AB, Yu M, Caterini J, Kim-Schulze S, Debenedette M, Salha D, Vogel T, Elias I, Berinstein NL. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res. 2008 Aug 01; 14(15):4843-9. PMID: 18676757.
    Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
  135. Mong PY, Petrulio C, Kaufman HL, Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol. 2008 Jan 01; 180(1):550-8. PMID: 18097057.
    Citations: 30     Fields:    Translation:Humans
  136. Sullivan ME, Ortega A, Wasserberg N, Kaufman H, Nyquist J, Clark R. Assessing the teaching of procedural skills: can cognitive task analysis add to our traditional teaching methods? Am J Surg. 2008 Jan; 195(1):20-3. PMID: 18082538.
    Citations: 8     Fields:    Translation:Humans
  137. Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J. Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med. 2007 Nov 26; 5:60. PMID: 18039393.
    Citations: 31     Fields:    Translation:HumansCellsCTClinical Trials
  138. Ugurel S, Schrama D, Keller G, Schadendorf D, Bröcker EB, Houben R, Zapatka M, Fink W, Kaufman HL, Becker JC. Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunol Immunother. 2008 May; 57(5):685-91. PMID: 17909797.
    Citations: 22     Fields:    Translation:Humans
  139. Kim-Schulze S, Taback B, Kaufman HL. Cytokine therapy for cancer. Surg Oncol Clin N Am. 2007 Oct; 16(4):793-818, viii. PMID: 18022545.
    Citations: 7     Fields:    Translation:HumansAnimals
  140. Suciu-Foca N, Feirt N, Zhang QY, Vlad G, Liu Z, Lin H, Chang CC, Ho EK, Colovai AI, Kaufman H, D'Agati VD, Thaker HM, Remotti H, Galluzzo S, Cinti P, Rabitti C, Allendorf J, Chabot J, Caricato M, Coppola R, Berloco P, Cortesini R. Soluble Ig-like transcript 3 inhibits tumor allograft rejection in humanized SCID mice and T cell responses in cancer patients. J Immunol. 2007 Jun 01; 178(11):7432-41. PMID: 17513794.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  141. Ward RC, Kaufman HL. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol. 2007 May-Aug; 26(3-4):161-96. PMID: 17558743.
    Citations: 6     Fields:    Translation:HumansCells
  142. Bereta M, Hayhurst A, Gajda M, Chorobik P, Targosz M, Marcinkiewicz J, Kaufman HL. Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies. Vaccine. 2007 May 22; 25(21):4183-92. PMID: 17399861.
    Citations: 8     Fields:    Translation:AnimalsCells
  143. Cesana GC, Romano F, Piacentini G, Scotti M, Brenna A, Bovo G, Vaghi M, Aletti G, Caprotti R, Kaufman H, Uggeri F. Low-dose interleukin-2 administered pre-operatively to patients with gastric cancer activates peripheral and peritumoral lymphocytes but does not affect prognosis. Ann Surg Oncol. 2007 Apr; 14(4):1295-304. PMID: 17225981.
    Citations: 2     Fields:    Translation:HumansCells
  144. Petrulio CA, Kim-Schulze S, Kaufman HL. The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther. 2006 Jul; 6(7):671-84. PMID: 16805707.
    Citations: 8     Fields:    Translation:HumansCells
  145. Eisenberger A, Elliott BM, Kaufman HL. Viral vaccines for cancer immunotherapy. Hematol Oncol Clin North Am. 2006 Jun; 20(3):661-87. PMID: 16762729.
    Citations: 2     Fields:    Translation:HumansCells
  146. Kaufman HL, Wolchok JD. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol. 2006 May 20; 24(15):2230-2. PMID: 16710020.
    Citations: 5     Fields:    Translation:HumansCells
  147. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL. 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine. 2006 Jun 05; 24(23):4975-86. PMID: 16621183.
    Citations: 15     Fields:    Translation:AnimalsCells
  148. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006 Mar 01; 24(7):1169-77. PMID: 16505437.
    Citations: 75     Fields:    Translation:HumansCells
  149. Kaufman HL, Cohen S, Cheung K, DeRaffele G, Mitcham J, Moroziewicz D, Schlom J, Hesdorffer C. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther. 2006 Feb; 17(2):239-44. PMID: 16454657.
    Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
  150. Petrulio CA, Kaufman HL. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines. 2006 Feb; 5(1):9-19. PMID: 16451103.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  151. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006 Jan 03; 4:1. PMID: 16390546.
    Citations: 48     Fields:    
  152. Flanagan K, Kaufman HL. Chemokines in tumor immunotherapy. Front Biosci. 2006 Jan 01; 11:1024-30. PMID: 16146794.
    Citations: 1     Fields:    Translation:HumansAnimals
  153. Kaufman HL. Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules. Ann N Y Acad Sci. 2005 Dec; 1062:41-50. PMID: 16461787.
    Citations:    Fields:    Translation:HumansCells
  154. Arlen PM, Kaufman HL, DiPaola RS. Pox viral vaccine approaches. Semin Oncol. 2005 Dec; 32(6):549-55. PMID: 16338420.
    Citations: 12     Fields:    Translation:HumansCells
  155. Komenaka IK, Nguyen ET, DeRaffele G, Mitcham J, Hurst-Wicker KS, Kaufman HL. The contralateral sentinel node. Can J Surg. 2005 Oct; 48(5):416-7. PMID: 16248145.
    Citations:    Fields:    Translation:Humans
  156. Kaufman HL, Divgi CR. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6757-62. PMID: 16203760.
    Citations: 3     Fields:    Translation:HumansCells
  157. Moroziewicz D, Kaufman HL. Gene therapy with poxvirus vectors. Curr Opin Mol Ther. 2005 Aug; 7(4):317-25. PMID: 16121697.
    Citations: 9     Fields:    Translation:HumansCells
  158. Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, Cheung K, Lee DS, Divito J, Voulo M, Donovan J, Dolan K, Manson K, Panicali D, Wang E, Hörig H, Marincola FM. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest. 2005 Jul; 115(7):1903-12. PMID: 15937544.
    Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
  159. Wadler S, Kaufman H, Horwitz M, Morley S, Kirn D, Brown R, Kaye S, Soutar D. The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin Cancer Res. 2005 Apr 01; 11(7):2781-2; author reply 2782. PMID: 15814661.
    Citations:    Fields:    Translation:HumansCells
  160. Komenaka IK, DeRaffele G, Hurst-Wicker KS, Kaufman HL. Management of metastatic melanoma to the breast with high-dose interleukin-2 and surgical resection. Breast J. 2005 Mar-Apr; 11(2):158-9. PMID: 15730472.
    Citations:    Fields:    Translation:Humans
  161. Flanagan K, Moroziewicz D, Kwak H, Hörig H, Kaufman HL. The lymphoid chemokine CCL21 costimulates naive T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cell Immunol. 2004 Sep-Oct; 231(1-2):75-84. PMID: 15919372.
    Citations: 25     Fields:    Translation:AnimalsCells
  162. Kaufman HL, Harandi A, Watson MC, Carter EL, DeRaffele G, Shahid M, Fine RL. Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. Lancet Oncol. 2005 Jan; 6(1):62-3. PMID: 15629278.
    Citations:    Fields:    Translation:Humans
  163. Kaufman HL. Integrating bench with bedside: the role of vaccine therapy in the treatment of solid tumors. J Clin Oncol. 2005 Feb 01; 23(4):659-61. PMID: 15613694.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  164. Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer Gene Ther. 2004 Dec; 11(12):808-18. PMID: 15359290.
    Citations: 7     Fields:    Translation:AnimalsCells
  165. Cohen S, Kaufman HL. TG-4010 Transgene. Curr Opin Investig Drugs. 2004 Dec; 5(12):1319-28. PMID: 15648954.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  166. Stoutenburg JP, Schrope B, Kaufman HL. Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther. 2004 Oct; 4(5):823-35. PMID: 15485316.
    Citations: 3     Fields:    Translation:Humans
  167. Flanagan K, Glover RT, Hörig H, Yang W, Kaufman HL. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine. 2004 Jul 29; 22(21-22):2894-903. PMID: 15246626.
    Citations: 5     Fields:    Translation:AnimalsCells
  168. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004 Jun 01; 22(11):2122-32. PMID: 15169798.
    Citations: 73     Fields:    Translation:HumansCTClinical Trials
  169. Komenaka I, Hoerig H, Kaufman HL. Immunotherapy for melanoma. Clin Dermatol. 2004 May-Jun; 22(3):251-65. PMID: 15262312.
    Citations: 12     Fields:    Translation:Humans
  170. Spanknebel K, Kaufman HL. Surgical treatment of stage IV melanoma. Clin Dermatol. 2004 May-Jun; 22(3):240-50. PMID: 15262311.
    Citations: 5     Fields:    Translation:Humans
  171. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther. 2004 Apr; 4(4):575-88. PMID: 15102606.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  172. Kaufman HL, Disis ML. Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest. 2004 Mar; 113(5):664-7. PMID: 14991063.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  173. Hörig H, Kaufman HL. Local delivery of poxvirus vaccines for melanoma. Semin Cancer Biol. 2003 Dec; 13(6):417-22. PMID: 15001160.
    Citations: 4     Fields: